You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

contiguous stage II adult diffuse mixed cell lymphoma

Showing 76 - 100 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Adult Diffuse Astrocytoma, Adult Mixed Glioma, Adult Oligodendroglioma Trial in San Francisco (Everolimus, Archival Tissue

Completed
Has Results
  • Adult Diffuse Astrocytoma
  • +4 more
  • San Francisco, California
    University of California, San Francisco
Jul 24, 2020

Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma, Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma, Ann

Completed
Has Results
  • Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma
  • +11 more
  • Laboratory Biomarker Analysis
  • +2 more
  • Mountain View, California
  • +90 more
Aug 3, 2022

Cervical Cancer, Chronic Myeloproliferative Disorders, Leukemia Trial in Los Angeles (Fragmin, )

Completed
  • Cervical Cancer
  • +8 more
  • Los Angeles, California
    Jonsson Comprehensive Cancer Center, UCLA
Jul 30, 2020

Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With

Completed
Has Results
  • Accelerated Phase Chronic Myelogenous Leukemia
  • +117 more
  • Ann Arbor, Michigan
    University of Michigan University Hospital
Jun 28, 2018

Chronic Myeloproliferative Disorders, GVHD, Leukemia Trial in Buffalo (sargramostim)

Completed
  • Chronic Myeloproliferative Disorders
  • +5 more
  • sargramostim
  • Buffalo, New York
    Roswell Park Cancer Institute
Oct 3, 2022

Lymphoma Trial in United States (biological, drug, radiation)

Completed
Has Results
  • Lymphoma
  • rituximab
  • +7 more
  • Anchorage, Alaska
  • +47 more
Dec 22, 2021

Recurrent DLBCL, Refractory DLBCL Trial in Houston (Chemotherapy, Computed Tomography, Fludeoxyglucose F-18)

Completed
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-Cell Lymphoma
  • Houston, Texas
    M D Anderson Cancer Center
Oct 27, 2022

Diffuse Large B Cell Lymphoma Trial (Pembrolizumab, Rituximab, Ifosfamide)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Headington, Oxford, United Kingdom
  • +1 more
Nov 2, 2022

Lymphoma Trial in Worldwide (Bendamustine, Obinutuzumab, Polatuzumab vedotin (Liquid))

Completed
Has Results
  • Lymphoma
  • Birmingham, Alabama
  • +61 more
Oct 18, 2022

Burkitt Lymphoma, KSHV-associated Multicentric Castleman Disease, DLBCL Trial in Kampala (Rituximab and Hyaluronidase Human,

Recruiting
  • Burkitt Lymphoma
  • +2 more
  • Rituximab and Hyaluronidase Human
  • +8 more
  • Kampala, Uganda
    UCI-Fred Hutch Cancer Centre
Mar 9, 2022

Cardiotoxicity of Anthracyclines in Diffuse Large B-Cell

Active, not recruiting
  • Lymphoma
  • +2 more
  • R-CHOP with doxorubicin
  • Messina, ME, Italy
  • +17 more
Apr 22, 2022

Diffuse Large B-cell Lymphoma Trial in Chapel Hill (Polatuzumab vedotin (PV), Rituximab, Hyaluronidase)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • Polatuzumab vedotin (PV)
  • +6 more
  • Chapel Hill, North Carolina
    Lineberger Comprehensive Cancer Center
Aug 9, 2022

Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Stage 0 Chronic Lymphocytic

Completed
  • Contiguous Stage II Small Lymphocytic Lymphoma
  • +5 more
  • Cleveland, Ohio
    Case Comprehensive Cancer Center
Jan 14, 2020

Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic

Completed
Has Results
  • Accelerated Phase Chronic Myelogenous Leukemia
  • +99 more
  • fludarabine phosphate
  • +4 more
  • Buffalo, New York
    Roswell Park Cancer Institute
Oct 30, 2019

DLBCL Trial (Polatuzumab Vedotin)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • Polatuzumab Vedotin
  • (no location specified)
Jul 12, 2023

Brain and CNS Tumors, Chronic Myeloproliferative Disorders, Leukemia Trial in Detroit, Cleveland, Philadelphia (educational

Completed
  • Brain and Central Nervous System Tumors
  • +8 more
  • educational intervention
  • Detroit, Michigan
  • +3 more
Jul 23, 2020

DLBCL Unclassifiable Trial in Houston (Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide)

Active, not recruiting
  • Diffuse Large B-Cell Lymphoma Unclassifiable
  • Houston, Texas
    M D Anderson Cancer Center
Feb 23, 2022

Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

Recruiting
  • Diffuse Large B-cell Lymphoma Recurrent
  • Diffuse Large B Cell Lymphoma Refractory
  • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Oct 12, 2023

Diffuse Large B Cell Lymphoma Trial in Shenyang (Zanubrutinib, Rituximab, Cyclophosphamide)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • Shenyang, Liaoning, China
    Xing Xiaojing
Jun 1, 2023

Diffuse Large B Cell Lymphoma (DLBCL) Trial in Toronto (glofitamab)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma (DLBCL)
  • Toronto, Ontario, Canada
    Princess Margaret Cancer Centre
Sep 18, 2023

Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma Trial

Active, not recruiting
  • Ann Arbor Stage II Follicular Lymphoma
  • +9 more
  • Houston, Texas
    M D Anderson Cancer Center
Feb 3, 2022

DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in Xiamen (Lenalidomide combined with G-CHOP (LO CHOP))

Recruiting
  • DLBCL - Diffuse Large B Cell Lymphoma
  • Follicular Lymphoma
  • Lenalidomide combined with G-CHOP (LO CHOP)
  • Xiamen, Fujian, China
    Bing Xu
Nov 28, 2023

T Cell Lymphoma Trial in New Haven (Mogamulizumab, DA-EPOCH Protocol)

Not yet recruiting
  • T Cell Lymphoma
  • New Haven, Connecticut
    Yale Smilow Cancer Hospital
Aug 14, 2023

Relapsed/Refractory Diffuse Large B Cell Lymphoma Trial in Seoul (Glofitamab, Poseltinib, Lenalidomide)

Recruiting
  • Relapsed/Refractory Diffuse Large B Cell Lymphoma
  • Glofitamab, Poseltinib, Lenalidomide
  • Seoul, Korea, Republic of
    Seoul National University Hospital
Nov 28, 2022

High-Dose Methotrexate Clearance in Diffuse Large B-Cell

Recruiting
  • Central Nervous System Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Non-Interventional Study
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 8, 2023